Glaucoma is called the silent thief of sight because it has no symptoms until vision is permanently lost. The only proven treatment? Lowering eye pressure with drugs. The ophthalmic drugs market research study shows that glaucoma is a major therapeutic area, with prostaglandin analogs (latanoprost, bimatoprost) being the first‑line treatment. They're effective, once‑daily, and have few side effects.

What's new? Fixed‑dose combinations (latanoprost + timolol) that reduce drop burden. Also, sustained‑release implants (Durysta) that lower pressure for months. The ophthalmic drugs market trends highlight that the fastest‑growing therapeutic area is retinal disorders (macular degeneration, diabetic retinopathy), but glaucoma remains the largest in terms of patient numbers.

But adherence is a problem. Many patients stop taking drops because they don't feel any different — until it's too late. That's why combination drops and sustained‑release implants are important.

The message: if you have glaucoma, take your drops every day. Even if you feel fine. The damage is silent, but it's real. And new technologies are making treatment easier.